RT Journal Article
SR Electronic
T1 Cross-reactive Bundibugyo antibody responses after licensed Ebola vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2026.05.27.26354223
DO 10.64898/2026.05.27.26354223
A1 Lhomme, Edouard
A1 Wiedemann, Aurélie
A1 Ayouba, Ahidjo
A1 Ben-Farhat, Safaa
A1 Thaurignac, Guillaume
A1 Roy, Céline
A1 Beavogui, Abdoul Habib
A1 Doumbia, Seydou
A1 Kieh, Mark
A1 Leigh, Bailah
A1 Sow, Samba
A1 Migueles, Stephen A
A1 Watson-Jones, Deborah
A1 Yazdanpanah, Yazdan
A1 Thiébaut, Rodolphe
A1 Peeters, Martine
A1 Richert, Laura
A1 Levy, Yves
A1 PREVAC study Team
YR 2026
UL http://medrxiv.org/content/early/2026/05/28/2026.05.27.26354223.abstract
AB Background The ongoing Bundibugyo virus disease (BDBV) outbreak in Central Africa highlights the absence of approved vaccines specifically targeting BDBV. Whether licensed Zaire ebolavirus (EBOV) vaccines induce cross-reactive immunity against BDBV remains largely unknown.Methods We performed an immunogenicity analysis using serum samples from participants enrolled in the PREVAC randomized clinical trial evaluating licensed Ebola vaccine strategies in West Africa. Samples collected at day 28 (D28) and month 3 (M3) following vaccination with rVSVΔG-ZEBOV-GP or Ad26.ZEBOV/MVA-BN-Filo were assessed using a multiplex Luminex assay against glycoproteins from multiple filoviruses, including EBOV Kikwit, EBOV Mayinga, BDBV, Sudan virus, Reston virus, and Marburg virus.Results A total of 179 samples were analysed. Detectable cross-reactive antibody responses against BDBV were observed across vaccine groups, timepoints, and age categories. However, BDBV responses remained substantially lower than homologous EBOV responses. In rVSV recipients, median BDBV responses (net MFI) reached 282 (IQR 164–644) at D28 compared with 1788 (832–3311) against the homologous Kikwit antigen. Similar patterns were observed following rVSV booster vaccination and Ad26.ZEBOV/MVA-BN-Filo vaccination. The heterologous Ad26/MVA regimen demonstrated increasing BDBV responses between D28 and M3.Conclusions Licensed EBOV vaccines induced detectable but quantitatively reduced cross-reactive antibody responses against BDBV. Although no direct assessment of vaccine efficacy against BDBV disease was possible, these findings support the plausibility of partial heterologous immunity following EBOV vaccination. In the absence of approved BDBV-specific vaccines, these data support the urgent evaluation of currently available Ebola vaccines during BDBV outbreaks and reinforce the importance of developing broadly protective pan-filovirus vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02876328Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol, the informed consent and assent forms, including participants information materials, were approved by ethics committees of the sponsors (INSERM IRB 00003888, LSHTM) and the implementing countries (Guinea, Liberia, Mali, and Sierra Leone) before each version of the protocol was implemented.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPREVAC pseudonymized data are sensitive data collected through a clinical trial. Therefore, for participants data protection and privacy, legal and ethical reasons, the PREVAC pseudonymized data cannot be shared publicly. The PREVAC metadata are available on the Recherche Data Gouv repository, DOI: 10.57745/PVXRMC (https://doi.org/10.57745/PVXRMC). Authorization for the use of the PREVAC/PREVAC-UP pseudonymized clinical and immunological data must be granted by the sponsors and the concerned country PIs. The final decision to either authorize or not the use of the data and data transfer lies with the sponsors in order to ensure the data request is in accordance with legal and ethical regulations. If a data request is granted, a DTA (data transfer agreement) must be established. For any additional question regarding access to the PREVAC/PREVAC UP pseudonymized data please contact: promoteur.inserm{at}inserm.fr. EDCTP2, RIA2017S-2014 – PREVAC-UPInnovative Medicines Initiative 2 Joint Undertaking, 115854, EBOVAC1NCI Information Systems (United States), https://ror.org/05mmhfh95, HHSN261201500003I, 75N91019D00024Inserm, https://ror.org/02vjkv261